Clinical trial
Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults:a Staggered Phase Ia/Ib, Randomised, Double-blind, Multi-Centre Trial
NCT02014727 is registered in ClinicalTrials.gov with Institut National de la Santé Et de la Recherche Médicale, France as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults:a Staggered Phase Ia/Ib, Randomised, Double-blind, Multi-Centre Trial
- Lead sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 31, 2014
- Completion date
- July 31, 2015
- Enrollment
- 66 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.